Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma

IMPORTANCE: Nivolumab plus ipilimumab (nivo + ipi) is a standard treatment of advanced melanoma. Two randomized trials describe high objective response rates by Response Evaluation Criteria in Solid Tumors. The trials assessed toxic effects using the Common Terminology Criteria for Adverse Events (C...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:JAMA Oncol
Egile Nagusiak: Shoushtari, Alexander N., Friedman, Claire F., Navid-Azarbaijani, Pedram, Postow, Michael A., Callahan, Margaret K., Momtaz, Parisa, Panageas, Katherine S., Wolchok, Jedd D., Chapman, Paul B.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Medical Association 2017
Gaiak:
Brief Report
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5833656/
https://ncbi.nlm.nih.gov/pubmed/28817755
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2017.2391
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak